2022 U.S.-Booked Air Volume: $26M
Consolidated Global TMC: BCD

U.S.-booked air volume at pharmaceutical giant AstraZeneca increased significantly to $26 million in 2022, up from $4.5 million in 2021, according to BTN estimates.

Global revenue followed a similar upward trajectory from $37 billion in 2021 to $44 billion last year. Emissions related to air travel in 2022 were 53 percent below the company’s 2019 baseline of 327,000 metric tons of carbon dioxide equivalent, according to AstraZeneca’s 2022 sustainability report.

The report also stated that “50 percent of our suppliers by spend covering upstream transportation and distribution and business travel will have science-based targets by 2025” and that the company will reduce greenhouse gas emissions related to upstream transportation and business travel by 46 percent by 2030.

Following a string of acquisitions in 2021 and 2022, the company has continued its buying spree into 2023, with an agreement to purchase U.S.-based biopharmaceutical company CinCor Pharma as well as a recent move to acquire and license Pfizer’s early-stage gene therapy portfolio for rare diseases. It also completed its acquisition of biotechnology company Neogene Therapeutics Inc. in January 2023.

AstraZeneca had 83,500 full-time employees in 2022, up 400 year over year.